INTRODUCTION {#s1}
============

Rectal cancer is one of the most common cancers in the world. Preoperative concurrent chemoradiotherapy (RTCT) is recommended as the first choice for locally advanced rectal cancer (LARC) based on several randomized controlled trials \[[@R1]--[@R4]\], yet in 2010, only 47.3% of such patients received preoperative radiotherapy (RT) in practice based on SEER program \[[@R5]\]. However, although resection based on the principles of total mesorectal excision (TME) has become the cornerstone of multimodality treatment since 1990s \[[@R6], [@R7]\], the evidence supporting the overall survival (OS) benefit from postoperative treatment is still sparse.

Many published studies have developed nomograms which are successful in predicting oncology events. Recently a study provided a nomogram based on five RCT in preoperative setting which accurately predicted the rate of overall survival, local recurrence and distant metastases, and that was successfully validated by a Chinese dataset \[[@R8], [@R9]\]. The aim of our study was to identify similar predicting factors of overall survival in postoperative rectal cancer patients and combine them into a nomogram for individualized treatment and further clinical trial design.

RESULTS {#s2}
=======

Follow-up analysis {#s2_1}
------------------

Patients eligible for the analysis were 1798, with a median follow-up time of 59.8 months, event rates at 5 years of follow-up were 23.8% for OS, and the 5-year OS was 73.8%. The clinical features are shown in Table [1](#T1){ref-type="table"}.

###### Clinical characteristics of 1798 patients

                   no. (%)                            no. (%)                               no. (%)
  ---------------- ------------- -------------------- ------------- ----------------------- -------------
  Age                            Grade of histology                 Type of local surgery   
   Median          56            High                 117 (6.5)     LAR                     1230 (68.4)
   Range           22-90         Moderate             1378 (76.6)   APR                     506 (28.1)
  Gender                         Low                  247 (13.7)    Hartmann                23 (1.3)
   Female          751 (41.8)    Unknown              56 (3.1)      LE                      26 (1.4)
   Male            1047 (58.2)   Pathology T stage                  Unknown                 13 (0.8)
  ECOG                           T1 or T2             178 (10.5)    RT                      1680 (93.4)
   0               549 (30.5)    T3                   1543 (85.8)   IMRT                    601 (33.4)
   1               810 (45.1)    T4                   64 (3.6)      RTCT                    1414 (78.6)
   2               6 (0.3)       Unknown              3 (0.2)       Adjuvant CT cycles      
   Unknown         433 (24.1)    Pathology N stage                  No                      787 (43.8)
  Tumor location                 0                    745 (41.4)    1-6                     680 (37.8)
   0-5cm           694 (38.6)    1                    607 (33.8)    \>6                     270 (15.0)
   5.1-10cm        693 (38.5)    2                    425 (23.6)    Unknown                 61 (3.4)
   10.1-15cm       149 (8.3)     Unknown              21 (1.2)                              
   Unknown         262 (14.6)                                                               

Pooled cox model analysis {#s2_2}
-------------------------

The survival analysis based on pooled 20 imputed dataset was conducted by multivariate Cox model, the results are in Table [2](#T2){ref-type="table"}. Based on the selected significant covariates, the overall P-value of each model calculated for each dataset was always \<1^−16^ meaning that the overall regression fit was largely significant. Table [2](#T2){ref-type="table"} also shows that in Kaplan-Meier analyses, baseline characteristics including gender, age and ECOG correlate significantly with OS. Variables of tumor, including pathological T stage, N stage and grade of histology have very significant impact on OS. In this analysis, adjuvant chemotherapy and concurrent radiochemotherapy improve prognosis significantly, even IMRT technique increases OS with marginal significance. AUC analysis was defined for each one of the imputed dataset and corresponding Cox model. The mean value of the AUC was 0.7226 (range 0.7187 - 0.7273). In bootstrap method, the corrected mean of AUC values was 0.7157 (range 0.7108 - 0.7217), not significantly different from the start AUC mean value. The final model was designed by using pooled coefficients derived from the analysis and its final performance in terms of c-index (AUC) was 0.7105. The plot of its ROC curve is shown in Figure [1](#F1){ref-type="fig"}. Finally the correlation analysis among covariates didn\'t show significant correlation among them.

###### Summary of multivariate Cox analysis and Kaplan Meier univariate analysis

  Name                   Cox multivariate analysis   Kaplan-meier univariate analysis                                                     
  ---------------------- --------------------------- ---------------------------------- ---------------- --------- -------- ------ ------ ---------
  Age                    .0156                       .0046                              .0065\~.0246     .0008     \<50     565    75.9   .003
                                                                                                                   51\~60   574    73.7   
                                                                                                                   61\~70   489    74.9   
                                                                                                                   \>70     170    65.1   
  Sex                    .2235                       .1008                              .0258\~.4211     .0267     Female   751    76.0   .039
                                                                                                                   Male     1047   72.4   
  ECOG                   .2455                       .1261                              .0033\~.4943     .0531     0        549    79.6   \<.0001
                                                                                                                   1-2      816    68.1   
  Grade of histology     .4582                       .1092                              .2442\~.6723     \<.0001   1        117    86.4   \<.0001
                                                                                                                   2        1378   76.2   
                                                                                                                   3        247    57.2   
  RTCT                   −.2532                      .1142                              −.4770\~-.0292   .0267     No       380    70.7   .015
                                                                                                                   Yes      1415   74.9   
  pT stage               .4117                       .1272                              .1624\~.6609     .0012     T1       23     90.9   \<.0001
                                                                                                                   T2       165    78.1   
                                                                                                                   T3       1543   73.9   
                                                                                                                   T4       64     55.6   
  pN stage               .6254                       .0683                              .4915\~.7592     \<.0001   N0       745    84.9   \<.0001
                                                                                                                   N1       607    73.4   
                                                                                                                   N2       425    54.6   
  Residual tumor         .6316                       .0882                              .4587\~.8044     .0001     R0       1706   75.8   \<.0001
                                                                                                                   R1       14     52.7   
                                                                                                                   R2       59     24.4   
  adjuvant CT cycles     −.0534                      .0161                              −.0849\~−.0219   .0009     0\~5     1151   72.6   .026
                                                                                                                   \>5      585    75.9   
  RT interruption days   .0169                       .0059                              .0053\~.0285     .0045     0-1      1619   74.6   .044
                                                                                                                   \>1      90     67.5   
  IMRT                   −.2508                      .1244                              −.4949\~0.0066   .0441     Yes      590    76.0   .052
                                                                                                                   No       1013   72.4   

![ROC curve of the final predictive model\
AUC=0.7105.](oncotarget-07-46536-g001){#F1}

Calibration and discrimination {#s2_3}
------------------------------

The result of calibration of the final model is in Figure [2](#F2){ref-type="fig"}. It shows almost perfect concordance between the predicted and the actual outcome obtained by Kaplan Meier overall survival estimator. The results of discrimination procedure are set up according to criteria 1b of TRIPOD statement \[[@R10]\]. In order to discriminate among different risk classes three categories of patients have been characterized by ranking them according the value of linear predictor of Cox model. The three survival curves are shown in Figure [3](#F3){ref-type="fig"}.

![Calibration plot of 5 years overall survival prediction model\
The calculated values of three prognostic groups (black circles) lie very close to the reference line of perfect calibration (red dash-dot line). The blue X shows the small movements in calibration achieved by bootstrapping procedure to decrease the overfitting of the model.](oncotarget-07-46536-g002){#F2}

![Kaplan Meier Overall Survival of the dataset with three prognostic groups\
The vertical line refers to the chosen time for model creation (60 months).](oncotarget-07-46536-g003){#F3}

Nomogram {#s2_4}
--------

The final nomogram (Figure [4](#F4){ref-type="fig"}) was generated for calculating the 5 years predicted overall survival. In order to compute the prediction value of a new case, each covariate has to be selected and the corresponding score on the top line has to be summed to other scores. The final value of score sum gives the corresponding value in the predicted survival at 60 months in the bottom line. The positioning of the patient within a prognosis group can be easily be achieved looking at the "linear predictor" reference rectangle, where the color code is the same as color code in Kaplan Meier survival curves in Figure [3](#F3){ref-type="fig"}.

![Nomogram for calculation of 5 years Overall Survival\
Each value in the covariates corresponds to a given score that can be obtained in the top line of the nomogram ("Points"). After summing all the scores for each covariate value the final sum has to be identified in the line "Total Points". Tracing a vertical line from "Total Points" line down to "5 Years OS Probability" line you can read the expected survival probability assigning the patients to one of the three prognostic groups used for model calibration.](oncotarget-07-46536-g004){#F4}

DISCUSSION {#s3}
==========

Based on a large database from our single center, we have developed a 5-year OS prediction model for staged II/III rectal cancer patients who received TME surgery. The relevance of prognostic factors in our model fit well with previous studies \[[@R11]--[@R14]\]. Given the distribution of treatment modality of this cohort, the model can support decision making in clinical practice and candidates selecting for future trials in postoperative LARC treatment.

In rectal cancer, prospective trials and retrospective comparisons only indicated the less toxicity and treatment response on par (or at least not inferior) with IMRT to those from historical reports of non-IMRT radiation \[[@R15]\]. In this multiple regression analysis, an amazing but controversial finding was that IMRT technique was associated with a significant improvement in OS. To more thoroughly evaluate this finding, given the possible not uniform application of IMRT, we took into account all the significant factors in Pearson test, including sex, age, ECOG, RTCT, pT, pN, chemotherapy and RT interruption days, residual tumor, results indicated no correlation with other significant covariates. Coupled with the Cox multiple analysis, these data suggest that the observed improvement in OS was significant for patients treated with IMRT compared to non-IMRT. Although it is unlikely to design a RCT trial to compare IMRT with conventional radiation on impact of OS, given these encouraging results based on large data, IMRT could be recommended in routine practice in experienced center in postoperative LARC treatment, despite the borderline significance in univariate log-rank test (p=0.052). A further work on different large dataset could be useful to confirm such conclusion by using a different verification dataset.

Some early trials in non-TME era supported postoperative concurrent radiochemotherapy through benefit in both local control and survival \[[@R16]--[@R19]\], which lead to the consensus in US for this modality in stage II/III disease \[[@R20]\]. Nowadays, preoperative radiochemotherapy is recommended as the first choice for these patients worldwide, which improves local control and toxicities with comparable OS \[[@R1], [@R21]--[@R23]\]. Unexpectedly, our data showed that the postoperative concurrent radiochemotherapy improved overall survival after TME surgery. To our knowledge, this was also the only one retrospective analysis based on a large cohort to document the effect of postoperative radiochemotherapy in TME era.

After TME surgery, overall survival of LARC patients primarily depends on the occurrence of distant metastases, however, adjuvant chemotherapy in these patients remains controversial despite several RCT have been performed \[[@R3], [@R24]--[@R27]\]. In our model, more cycles of chemotherapy improved prognosis of patients in overall survival. Recently, a large meta-analysis indicated the benefit of adjuvant chemotherapy in DFS and OS \[[@R28]\]. Furthermore, similar results has been confirmed in ADORE study \[[@R29]\] and the previous nomogram in preoperative setting \[[@R8]\]. Further investigation is needed to define the role of adjuvant chemotherapy in the multimodal treatment of LARC patients to improve the encouraging findings of our results.

Although postoperative RTCT and CT both benefited OS in our data as mentioned above, debate still continues on whether they are both necessary for all LARC after TME surgery \[[@R25], [@R30]\]. As TME surgery technique alone can decrease the LR rate from 15%\~40% to less than 10% \[[@R31]--[@R33]\], and preoperative or postoperative adjuvant radiation can further improve local control despite OS benefits are still controversial \[[@R1], [@R22], [@R34], [@R35]\], and then new questions arise which subgroup of patients is the best candidate for adjuvant treatment to improve OS. In the last decade, there is an evolving and progressive expectation for individualized treatment, our nomogram is a decision tool designed to tailor adjuvant treatments in LARC. For potential applying, our model also proposed three prognostic groups (Figure [3](#F3){ref-type="fig"}), and different treatment strategies could be considered for each category. For example, when a "bad" prognostic patient (male, age 53 years, pT3N2, ECOG=1, grade of histology=3) after R0 resection is compared with a "good" prognostic one (female, age 43 years, pT3N0, ECOG=0, grade of histology=2), if RTCT with IMRT technique and adjuvant CT are applied, the 5-year OS may increase from 33.0% to 62.0% for "bad" and 86.0% to 90.0% for "good" respectively (Figure [4](#F4){ref-type="fig"}). Considering the potential morbidity \[[@R36], [@R37]\], cost of RT and CT, this particular "good" prognostic patient might choose to avoid adjuvant treatment given the minimal expected benefit.

Nomogram has been successfully developed for predicting OS in rectal cancer \[[@R8]\]. In addition to estimates of baseline overall survival, our model also provides individualized estimates of potential benefit from adjuvant radiochemotherapy, chemotherapy and IMRT technique. Future prospective studies are needed to more accurately refine indications of adjuvant treatment in these patients. The proposed nomogram performed well in predicting OS with a reliable c-index (0.7105) for internal validation and an excellent result in calibration, but it is still not optimal. Integration with other bioinformation would be expected to increase model accuracy.

There are several limitations that have to be considered for this study. First, the retrospective analysis, despite the strict application of the ontology for decreasing the data collection uncertainty level, did not overcome all uncertainties related to tumor recurrence pattern, surgical quality control by pathologists and treatment heterogeneity (especially chemotherapy regimens). Second, the span of time in this dataset is 10 years, a question might be raised about whether there\'s change of diagnosis technique through time. Finally, before generalized applying of this nomogram, we expect an independent data to validate using a coherent data ontology classification. In our setting the analysis type 1b according to TRIPOD statement finally ensures the best modeling procedure to take into account the different imputed dataset without splitting the cohort or using different modeling approaches \[[@R10]\].

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

In this study a large cohort of patients with histologically proven rectal cancer, pathologically staged as LARC by surgical histological specimen, has been analyzed. The initial dataset included 3995 patients from whom only post-operative radiotherapy cases with complete follow up record were selected. They were treated in our institution since 2000 to 2010. Metastatic patients were excluded from analysis. All patients received a TME procedure, even if the report of the completeness of the mesorectum removal was not available for all patients. Selection criteria included the availability of a follow up time record and the life status of the patients. This study was registered with [ClinicalTrials.gov](http://ClinicalTrials.gov), number NCT02312284.

The variables {#s4_2}
-------------

The evaluated variables were classified and collected according to a previously created ontology framework \[[@R38]\]. We included in this analysis the main epidemiological and oncological features for which a percentage of available records not lower than 90% was reachable. Sex, age at the date of diagnosis, tumor location (location was categorized on the basis of the tumor distance measured from the anorectal verge: low, less than 5cm; mid, 5 to 10cm; and high, more than 10cm), grade of histology, concurrent CT (yes/no), type of local surgery (low anterior resection \[LAR\] and abdominoperineal resection \[APR\]), pathological T stage, pathological N stage, presence of positive intestinal margin, residual tumor (absence, microscopic or macroscopic), adjuvant RTCT, number of adjuvant chemotherapy cycles, type of postoperative RT field (RT volume included tumor bed for R0 reseciton or Simultaneously Integrated Boost on residual tumor), postoperative RT delivered dose, fraction dose, number of RT unexpected interruption days, and IMRT technique were the analyzed features. Overall survival was selected as evaluated outcome, all causes of death at 5-year were included.

Statistical analysis {#s4_3}
--------------------

Overall missing data was 9.3% among this patients subset, allowing to perform the imputation procedure with a reasonable safety \[[@R39]\]. In order to ensure that the maximum number of patients was valuable without excluding patients missing only few records, a Multivariate Imputation by Chained Equations procedure was adopted \[[@R40]\]. This procedure allows to achieve more robust models by pooling the results calculated from each imputed datasets analysis, without decreasing the overall informative power due to patients exclusion. This imputation process takes into account for the process that created the missing data, preserves the relations in the data, and preserves the uncertainty about these relations. Imputation process multivariate analysis, by Cox proportional hazards regression, was performed using 20 imputed dataset derived from original one. The inclusion of covariates was achieved by backwards elimination of not significant ones deleting those showing P-value\>0.10 and considering significant covariates with P-value ≤0.05. Possible correlation among different covariates in the final model was evaluated by using Pearson correlation test. In order to analyze the performance of the models analysis of the Area Under the Curve (AUC) of Receiving Operating Characteristic (ROC) and calibration on Kaplan-Meier predictors were performed. Both AUC and calibration procedures were tuned using bootstrap in order to decrease the overfitting in the original models. The final results of coefficients, p-values in Cox models, AUC and calibration plots were pooled by calculating means of single imputed dataset.
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